Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post-failed external beam radiation therapy

Canadian Urological Association Journal

Volumn 8, Issue 9-10, 2014, Pages e708-e714

  Barrett, Tristan ^a   Davidson, Sean R H ^b   Wilson, Brian C ^b   Weersink, Robert A ^b   Trachtenberg, John ^a   Haider, Masoom A ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919879951     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.2176     Document Type: Article

References (26)

1. Arcangeli G, Strigari L, Arcangeli S, et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:975-82. http://dx.doi.org/10.1016/j.ijrobp.2008.12.045
2. Horwitz EM. Why external beam radiotherapy is treatment of choice for most men with early-stage nonmetastatic prostate cancer. Urology 2009;73:470-2. http://dx.doi.org/10.1016/j.urology.2008.09.029
3. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003;57:915-28. http://dx.doi.org/10.1016/S0360-3016(03)00632-1
4. Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: Additional diagnoses and avoided deaths. Ann Oncol 2012;23:1325-34. http://dx.doi.org/10.1093/annonc/mdr414
5. Roach M. The role of PSA in the radiotherapy of prostate cancer. Oncology (Williston Park) 1996;10:1143-53; discussion 1154-61.
6. Rocco B, Cozzi G, Spinelli MG, et al. Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer. Curr Urol Rep 2012;13:195-201. http://dx.doi.org/10.1007/s11934-012-0245-1
7. Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration. Eur Urol 2011;60:205-10. http://dx.doi.org/10.1016/j.eururo.2011.03.011
8. Nguyen PL, D'Amico AV, Lee AK, et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature. Cancer 2007;110:1417-28. http://dx.doi.org/10.1002/cncr.22941
9. Rogers E, Ohori M, Kassabian VS, et al. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 1995;153:104-10. http://dx.doi.org/10.1097/00005392-199501000-00037
10. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: A review. Curr Opin Urol 2009;19:283-9. http://dx.doi.org/10.1097/MOU.0b013e32832a2c4a
11. Haider MA, Davidson SR, Kale AV, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007;244:196-204. http://dx.doi.org/10.1148/radiol.2441060398
12. Davidson SR, Weersink RA, Haider MA, et al. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol 2009;54:2293-313. http://dx.doi.org/10.1088/0031-9155/54/8/003
13. Betrouni N, Lopes R, Puech P, et al. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11. Phys Med Biol 2011;56:4771-83. http://dx.doi.org/10.1088/0031-9155/56/15/009
14. Azzouzi AR, Barret E, Moore CM, et al. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 2013;112:766-74. http://dx.doi.org/10.1111/bju.12265
15. Chen Q, Huang Z, Luck D, et al. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol 2002;76:438-45. http://dx.doi.org/10.1562/0031-8655(2002) 076<0438:PSINCP>2.0.CO;2
16. Eymerit-Morin C, Zidane M, Lebdai S, et al. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch 2013;463:547-52. http://dx.doi.org/10.1007/s00428-013-1454-9
17. Gangi A, Tsoumakidou G, Abdelli O, et al. Percutaneous MR-guided cryoablation of prostate cancer: Initial experience. Eur Radiol 2012;22:1829-35. http://dx.doi.org/10.1007/s00330-012-2411-8
18. Kirkham AP, Emberton M, Hoh IM, et al. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008;246:833-44. http://dx.doi.org/10.1148/radiol.2463062080
19. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladiumbacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: Assessment of safety and treatment response. J Urol 2007;178:1974-9. http://dx.doi.org/10.1016/j.juro.2007.07.036
20. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425-30. http://dx.doi.org/10.1016/j.ijrobp.2007.06.029
21. Leisenring W, Pepe MS, Longton G. A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med 1997;16:1263-81. http://dx.doi.org/10.1002/(SICI)1097-0258(19970615) 1611<1263::AID-SIM550>3.0.CO;2-M
22. Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. The American Statistician 1998;52:119-26.
23. Villers A, Lemaitre L, Haffner J, et al. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. Curr Opin Urol 2009;19:274-82. http://dx.doi.org/10.1097/MOU.0b013e328329a2ed
24. Moman MR, van den Berg CA, Boeken Kruger AE, et al. Focal salvage guided by T(2)-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 2010;76:741-6. http://dx.doi.org/10.1016/j.ijrobp.2009.02.055
25. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5:497-508. http://dx.doi.org/10.1016/S1470-2045(04)01529-3
26. Coleman J, Scherz A. Focal therapy of localised prostate cancer by vascular targeted photodynamic therapy with WST-11 (TOOKAD® Soluble). Eur Urol Rev 2012;72:106-8.